To sum up, we believe that assessing whether VC can replace rapamycin (an inhibitor of the mTOR signaling pathway) to a certain degree for the treatment of specific tumors in relevant mouse models or replace rapamycin in combination with multiple drugs in order to induce the synergistic killing of cancer cells would be worthwhile for future studies. Here, MTOR is linked to cancer.